Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 34, 2021 - Issue 2
11
Views
0
CrossRef citations to date
0
Altmetric
Case Studies

Metastatic adult Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in complete remission

, MDORCID Icon, , MBBS & , MD
Pages 299-301 | Received 06 Aug 2020, Accepted 02 Nov 2020, Published online: 14 Dec 2020

  • National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed August 7, 2020.
  • Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112(7):1607–1616. doi:10.1002/cncr.23331.
  • Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15(4):1170–1176. doi:10.1158/1078-0432.CCR-08-1183.
  • Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42(4):369–373. doi:10.3109/00313021003767348.
  • Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149–1160. doi:10.1097/PAS.0b013e318031ffff.
  • He J, Chen X, Gan W, et al. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review. Future Oncol. 2015;11(24):3243–3252. doi:10.2217/fon.15.177.
  • Kuroda N, Mikami S, Pan CC, et al. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. Histol Histopathol. 2012;27(2):133–140. doi:10.14670/HH-27.133.
  • Liu C, Zhang W, Song H. Nephron-sparing surgery in the treatment of pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions. J Pediatr Surg. 2017;52(9):1492–1495.
  • Liu N, Wang Z, Gan W, et al. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical features, treatments and prognosis. PLoS One. 2016;11(11):e0166897.
  • Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67(3):919–929. doi:10.1158/0008-5472.CAN-06-2855.
  • Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010;21(9):1834–1838.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.